Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
12 September 2024 - 9:30PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE
13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of September, 2024
Commission File Number 001-41666
CASI PHARMACEUTICALS, INC.
(Translation of registrant’s name into English)
1701-1702, China Central Office Tower 1
No. 81 Jianguo Road, Chaoyang District
Beijing, 100025
People’s Republic of China
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F x Form 40-F ¨
CASI Pharmaceuticals Announces Change of Senior
Management Positions
On September 12, 2024, CASI Pharmaceuticals, Inc.,
a Cayman Islands incorporated company (“CASI” or the “Company”) announced that, to support the strategic pivot
of business operations and streamline the internal management reporting, effective from September 10, 2024, the position of President
of the Company was removed, and instead a Senior Vice President in charge of coordination and management of synergistic projects between
China and US and management of certain key projects was created. Mr. Wei (Larry) Zhang was appointed as the Senior Vice President.
“This adjustment
to our management structure shows our dedication to grow our business and coordinate our synergistic projects between China and US in
an efficient way,” said Dr.Wei-Wu He, Chairman and CEO of CASI, “We greatly appreciate Larry’s significant contribution
to our business growth as the President over the years and his commitment to the new role. We believe his profound management experience
and in-depth understanding of our business will contribute to the strategic pivot of our business, and we hope the adjustment will help
lighten his management burden in order for him to focus on our key development plans.”
Forward-Looking Statements
This 6-K contains forward-looking statements.
These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995.
These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,”
“future,” “intends,” “plans,” “believes,” “estimates,” “confident”
and similar statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities
and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and
in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including
statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent
risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking
statement. All information provided herein is as of the date of this 6-K, and the Company undertakes no obligation to update any forward-looking
statement, except as required under applicable law. We caution readers not to place undue reliance on any forward-looking statements contained
herein.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
CASI Pharmaceuticals, Inc. |
|
|
|
By: |
/s/ Wei-Wu He |
|
Name: |
Wei-Wu He |
|
Title: |
Chairman & CEO |
|
|
Date: September 12, 2024 |
|
|
CASI Pharmaceuticals (NASDAQ:CASI)
Historical Stock Chart
From Nov 2024 to Dec 2024
CASI Pharmaceuticals (NASDAQ:CASI)
Historical Stock Chart
From Dec 2023 to Dec 2024